Supplementary material to article by M. Inzinger et al. "Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria"

Table SVI. Psoriasis Area and Severity Index (PASI) reduction at 4 months achieved with anti-tumour necrosis factor-α agents for the different types of analyses

	Treatment cycles, n (%) ^a		
Category of PASI reduction	Adalimumab	Etanercept	Infliximab
	Intention-to-treat analysis		
Complete remission	52 (12.8)	34 (7.6)	8 (15.1)
PASI 90	145 (35.7)	95 (21.2)	27 (50.9)
PASI 75	264 (65.0)	223 (49.7)	37 (69.8)
PASI 50	333 (82.0)	365 (81.3)	47 (88.7)
	Per-protocol analysis, as described in Materials and Methods		
Complete remission	49 (12.7)	30 (7)	6 (11.1)
PASI 90	140 (36.6)	90 (21)	25 (46.3)
PASI 75	255 (66.1)	215 (50.1)	35 (64.8)
PASI 50	321 (83.2)	353 (82.3)	45 (83.3)

^aThe percentages refer to the total number of treatment cycles that were available at 4 months of treatment.

PASI 90, PASI 75 or PASI 50, reduction of PASI by at least 90%, 75% or 50%, respectively, from start of treatment.